Allergan's Latisse is a repackaged version of its Lumigan glaucoma drug. Many of us taking glaucoma eye drops would love to be able to stop using them due to the side effects. I find it disturbing that Allergan hopes to earn $500 million per year in revenue from selling this glaucoma drug as a means to lengthen eye lashes for cosmetic purposes. Sure, there are some individuals who have a genuine need for such a medication, but in order to reach their $500 million sales target, Allergan is going to have to sell a lot of this drug to average people without a genuine medicine need for it.
Only registered users have access to the most valuable content of the FitEyes community: Blogs, Comments, FitEyes Discussion Group Archives, unique information on self-tonometry and other user-generated research.
You must register because we have content that cannot be viewed unless you agree to our terms and conditions.